2015 Antineoplastics

STIs that target Bcr-Abl: DASATINIB, IMATINIB, NILOTINIB

Example QuestionTherapeutic Uses

Era
Discovery
Drug Treatment
Strategy
Survival
Success
1900
Disease
None
31 months
0%
1960
Ph chromosome
Kill all rapidly dividing cells
35-67 months
1980
Bcr-Abl gene
Decrease cell proliferation
55-89 months
20-30% cytogenic;
80% hematologic
2001
Signal transduction inhibitor
IMATINIB
Suppress defective enzyme
> 5 years
50-95% cytogenic
(depending upon phase)

Bone marrow transplant is still the only curative therapy (30-50% of patients).
However, patients over 60 do not qualify and not all patients can find a donor
overall cure rate for BMT is under 15%

Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 11-apr-15 9:39 AM